Oxcarbazepine (All indications)

Low Apgar score (< 7) (at 1 min)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9042
R30867		 Bank (Oxcarbazepine) (Mixed indications), 2017 Apgar < 7 at 1 minute during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 1.91 [0.08;48.39] C 0/4   2/36 2 4
ref
S9036
R30804		 Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 1-min Apgar <7 3rd trimester population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 0.99 [0.46;2.16] C
excluded (control group) 		27/465   9/154 36 465
ref
S9037
R30816		 Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013 1-min Apgar <7 3rd trimester population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.33 [0.90;1.97]
excluded (control group) 		27/465   27,939/689,482 27,966 465
ref
S9038
R30828		 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 1-min Apgar <7 3rd trimester population based cohort retrospective unexposed, sick Adjustment: Yes 1.33 [0.83;2.12] 27/465   69/1,708 96 465
ref
Total 2 studies 1.34 [0.84;2.13] 98 469
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bank (Oxcarbazepine) (Mixed indications), 2017Bank, 2017 1 1.91[0.08; 48.39]242%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Artama (Oxcarbazepine) (Controls unexposed, sick), 2013Artama, 2013 2 1.33[0.83; 2.12]9646598%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.34[0.84; 2.13]984690.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Mixed indications; 2: Oxcarbazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.34[0.84; 2.13]984690%NABank (Oxcarbazepine) (Mixed indications), 2017 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.33[0.83; 2.13]96465 -NAArtama (Oxcarbazepine) (Controls unexposed, sick), 2013 1 exposed to other treatment, sickexposed to other treatment, sick 1.91[0.08; 48.39]24 -NABank (Oxcarbazepine) (Mixed indications), 2017 1 Tags Adjustment   - No  - No 1.91[0.08; 48.39]24 -NABank (Oxcarbazepine) (Mixed indications), 2017 1   - Yes  - Yes 1.33[0.83; 2.13]96465 -NAArtama (Oxcarbazepine) (Controls unexposed, sick), 2013 1 All studiesAll studies 1.34[0.84; 2.13]984690%NABank (Oxcarbazepine) (Mixed indications), 2017 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9036, 9037

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.33[0.90; 1.97]27,966465 -NAArtama (Oxcarbazepine) (Controls unexposed, disease free), 2013 1 unexposed, sick controlsunexposed, sick controls 1.33[0.83; 2.13]96465 -NAArtama (Oxcarbazepine) (Controls unexposed, sick), 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.03[0.48; 2.19]384690%NABank (Oxcarbazepine) (Mixed indications), 2017 Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 20.510.01.0